1832 Asset Management
PPH icon

1832 Asset Management’s VanEck Pharmaceutical ETF PPH Stock Holding History

1832 Asset Management’s Portfolio PPH Stock Details PPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,748
Closed -$261K – 712
2024
Q3 		$261K Buy
+2,748
New +$261K ﹤0.01% 651

Other funds holding PPH

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
AT
Avalon Trust Santa Fe, New Mexico $1.45B AUM 35.31% 1-Year Est. Return
JSAM
J. Safra Asset Management New York $1.86B AUM 22.95% 1-Year Est. Return
MTWSIF
Mivtachim The Workers Social Insurance Fund Tel Aviv, Israel $789M AUM 73.25% 1-Year Est. Return
MIM
Miller Investment Management West Conshohocken, Pennsylvania $1.01B AUM 13.96% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
AWC
Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

1832 Asset Management's PPH Position: Q4 2024 in Review

1832 Asset Management sold out of VanEck Pharmaceutical ETF (PPH) in Q4 2024, closing a stake of 2,748 shares — an estimated $261K sold.

1832 Asset Management first reported a position in PPH in Q3 2024 and held it in 1 quarter. The position peaked at $261K in Q3 2024. 142 funds tracked by Wall St. Rank hold PPH as of Q4 2024.

  • 1832 Asset Management reported no remaining VanEck Pharmaceutical ETF position as of Q4 2024 after selling out during the quarter.
  • 1832 Asset Management sold 2,748 VanEck Pharmaceutical ETF shares in Q4 2024, an estimated $261K.
  • 1832 Asset Management first reported a position in VanEck Pharmaceutical ETF in Q3 2024 and held it in 1 quarter.
  • 1832 Asset Management's VanEck Pharmaceutical ETF position peaked at $261K in Q3 2024.
  • 142 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q4 2024.

Based on 1832 Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.